Cross-Sector entity
GLP-1 is the most frequent co-covered peer, appearing in 2 of the 3 tracked stories. earnings accounts for 1 of the 3 tracked stories, while 2 other categories carry the remainder. Madrigal Pharmaceuticals appears in 3 tracked Cross-Sector stories from February 24, 2026.
3 verified stories tracked
Last mentioned: Feb 24, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
GLP-1 is the most frequent co-covered peer, appearing in 2 of the 3 tracked stories. earnings accounts for 1 of the 3 tracked stories, while 2 other categories carry the remainder. Madrigal Pharmaceuticals appears in 3 tracked Cross-Sector stories from February 24, 2026. The tracked stories average 5 original sources each.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Madrigal Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
Payer Agreement Shift
New payer contracts take effect, shifting GTN expectations to the high 30% range for the fiscal year.
Q4 Milestone
Patient count surpasses 36,000 and quarterly revenue exceeds $320 million.
Patent Extension
Secured Rezdiffra patent protection through 2045.
DGAT-2 and siRNA Expansion
Acquired late-stage DGAT-2 inhibitor and six preclinical siRNA assets.
GLP-1 Strategic Acquisition
Madrigal makes a $120 million upfront payment for an oral GLP-1 asset to expand its metabolic pipeline.
GLP-1 Acquisition
Madrigal paid $120 million upfront to acquire an oral GLP-1 program.
Rezdiffra Commercial Launch
First full year of Rezdiffra availability in the U.S. market for MASH.
Rezdiffra Full-Year Launch
Madrigal begins its first full year of commercial sales for the first-ever approved MASH treatment.
Madrigal Pharmaceuticals reported a transformative 2025, with Rezdiffra net sales reaching $958.4 million during its first full year on the market. The company is aggressively pivoting toward a multi-asset metabolic powerhouse, integrating oral GLP-1 and DGAT-2 programs alongside its core MASH franchise.
The Q4 2025 earnings cycle reveals a retail landscape defined by digital efficiency and premiumization, with Carvana and Freshpet posting double-digit volume growth. Companies are increasingly leveraging loyalty ecosystems and strategic partnerships to drive margins in a stabilizing consumer market.
Madrigal Pharmaceuticals reported a transformative Q4 2025, with Rezdiffra net sales reaching $321.1 million and a patient base exceeding 36,000. The company is aggressively expanding its metabolic pipeline, integrating GLP-1 and siRNA technologies to solidify its leadership in the MASH market.
Source: Motley Fool Transcribing (us) · Motley Fool Transcribing (us)
